Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsPRNewsWire • 09/09/24
Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 DiabetesPRNewsWire • 09/04/24
Genprex to Present and Participate at Upcoming September Investor and Industry ConferencesPRNewsWire • 09/03/24
Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical TrialsPRNewsWire • 08/15/24
Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung CancerPRNewsWire • 08/14/24
Genprex Granted Patent in Singapore for Reqorsa® Gene Therapy with PD-1 Antibodies to Treat CancersPRNewsWire • 08/13/24
Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung CancerPRNewsWire • 05/14/24
Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of DirectorsPRNewsWire • 05/13/24
Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney VarnerPRNewsWire • 05/08/24
Genprex to Present and Participate at Upcoming May Investor and Industry ConferencesPRNewsWire • 05/01/24
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual MeetingPRNewsWire • 04/09/24
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung CancerPRNewsWire • 04/03/24
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery SystemPRNewsWire • 04/02/24
Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesPRNewsWire • 03/22/24
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesPRNewsWire • 03/19/24
Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat CancersPRNewsWire • 03/12/24
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual MeetingPRNewsWire • 03/06/24
Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research CollaboratorsPRNewsWire • 02/07/24
Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung CancerPRNewsWire • 02/05/24